Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | LCAT | P04180 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2145686 | 0.91 | DGAT1 (0.62) | DGAT1RXFP1LCATMLYCDSOAT2 | |
| SCHEMBL12246277 | 0.90 | DGAT1 (0.52) | DGAT1RXFP1LCATMLYCDSOAT2 | |
| SCHEMBL2145954 | 0.87 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL2145775 | 0.87 | DGAT1 (0.50) | DGAT1LCAT | |
| SCHEMBL13366319 | 0.85 | DGAT1 (0.42) | DGAT1NOTUM | |
| SCHEMBL12246295 | 0.84 | DGAT1 (0.55) | DGAT1RXFP1LCATMLYCD | |
| SCHEMBL2380357 | 0.83 | DGAT1 (0.50) | DGAT1RXFP1MLYCD | |
| SCHEMBL12246303 | 0.82 | DGAT1 (0.51) | DGAT1RXFP1LCATMLYCDNOTUM | |
| SCHEMBL12246291 | 0.80 | DGAT1 (0.49) | DGAT1RXFP1LCAT | |
| SCHEMBL2145146 | 0.80 | MEN1 (0.50) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| EP-2346853-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010059606-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885RXFP1 3398/4885LCAT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.